NEUROCRINE BIOSCIENCES INC.
NEUROCRINE BIOSCIENCES INC.
- USD (-)
- 15 min delayed data - NASDAQ Stocks
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: NBIX
ISIN:

Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

  • 44
Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Live Audio Webcast Will be on September 11, 2017

PR Newswire

SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York City.

The live presentation takes place on Monday, September 11 at 11:05am ET (8:05am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA® (valbenazine) in the United States for the treatment of adults with tardive dyskinesia.  INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with tardive dyskinesia.  The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 

View original content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-conference-300514871.html

SOURCE Neurocrine Biosciences, Inc.

PR Newswire
PR Newswire

PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.